FibroGen Inc (FGEN) CEO Sells $1,227,900.00 in Stock

FibroGen Inc (NASDAQ:FGEN) CEO Thomas B. Neff sold 30,000 shares of the stock in a transaction on Thursday, December 6th. The shares were sold at an average price of $40.93, for a total value of $1,227,900.00. Following the completion of the transaction, the chief executive officer now directly owns 2,646,320 shares in the company, valued at approximately $108,313,877.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of NASDAQ FGEN traded down $0.41 during trading hours on Thursday, hitting $40.93. The company’s stock had a trading volume of 455,900 shares, compared to its average volume of 530,083. The company has a debt-to-equity ratio of 0.20, a current ratio of 6.76 and a quick ratio of 6.76. The stock has a market capitalization of $3.51 billion, a PE ratio of -23.66 and a beta of 2.13. FibroGen Inc has a 12 month low of $37.85 and a 12 month high of $68.55.

FibroGen (NASDAQ:FGEN) last posted its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by ($0.15). The business had revenue of $29.00 million during the quarter, compared to the consensus estimate of $36.48 million. FibroGen had a negative return on equity of 24.59% and a negative net margin of 87.84%. FibroGen’s revenue was down 28.6% compared to the same quarter last year. As a group, equities research analysts anticipate that FibroGen Inc will post -1.55 earnings per share for the current year.

A number of research analysts have recently issued reports on the company. TheStreet cut FibroGen from a “c-” rating to a “d+” rating in a research note on Wednesday, November 21st. Zacks Investment Research cut FibroGen from a “buy” rating to a “hold” rating in a research note on Tuesday, November 13th. BidaskClub cut FibroGen from a “buy” rating to a “hold” rating in a research note on Tuesday, October 23rd. Leerink Swann set a $84.00 price objective on FibroGen and gave the company a “buy” rating in a research note on Monday, October 15th. Finally, ValuEngine cut FibroGen from a “strong-buy” rating to a “buy” rating in a research note on Monday, September 17th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $72.25.

Several hedge funds and other institutional investors have recently bought and sold shares of FGEN. Aperio Group LLC grew its stake in shares of FibroGen by 56.3% in the second quarter. Aperio Group LLC now owns 7,004 shares of the biopharmaceutical company’s stock worth $438,000 after purchasing an additional 2,523 shares during the last quarter. TD Asset Management Inc. grew its stake in shares of FibroGen by 20.2% in the second quarter. TD Asset Management Inc. now owns 46,426 shares of the biopharmaceutical company’s stock worth $2,906,000 after purchasing an additional 7,800 shares during the last quarter. Jennison Associates LLC grew its stake in shares of FibroGen by 61.9% in the second quarter. Jennison Associates LLC now owns 526,343 shares of the biopharmaceutical company’s stock worth $32,949,000 after purchasing an additional 201,289 shares during the last quarter. Alps Advisors Inc. grew its stake in shares of FibroGen by 9.7% in the second quarter. Alps Advisors Inc. now owns 120,666 shares of the biopharmaceutical company’s stock worth $7,554,000 after purchasing an additional 10,673 shares during the last quarter. Finally, State of Wisconsin Investment Board grew its stake in shares of FibroGen by 15.3% in the second quarter. State of Wisconsin Investment Board now owns 76,100 shares of the biopharmaceutical company’s stock worth $4,764,000 after purchasing an additional 10,100 shares during the last quarter. 64.86% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This report was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://sportsperspectives.com/2018/12/06/fibrogen-inc-fgen-ceo-sells-1227900-00-in-stock.html.

About FibroGen

FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.

Further Reading: Earnings Per Share

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply